ZA201804326B - Therapeutic cd47 antibodies - Google Patents

Therapeutic cd47 antibodies

Info

Publication number
ZA201804326B
ZA201804326B ZA2018/04326A ZA201804326A ZA201804326B ZA 201804326 B ZA201804326 B ZA 201804326B ZA 2018/04326 A ZA2018/04326 A ZA 2018/04326A ZA 201804326 A ZA201804326 A ZA 201804326A ZA 201804326 B ZA201804326 B ZA 201804326B
Authority
ZA
South Africa
Prior art keywords
antibodies
therapeutic
Prior art date
Application number
ZA2018/04326A
Other languages
English (en)
Inventor
Manning Pamela
Puro Robyn
C Almagro Juan
W Karr Robert
Original Assignee
Arch Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58289729&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201804326(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Arch Oncology Inc filed Critical Arch Oncology Inc
Publication of ZA201804326B publication Critical patent/ZA201804326B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
ZA2018/04326A 2015-09-18 2018-06-27 Therapeutic cd47 antibodies ZA201804326B (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201562220691P 2015-09-18 2015-09-18
US201562220725P 2015-09-18 2015-09-18
US201562221852P 2015-09-22 2015-09-22
US201562232681P 2015-09-25 2015-09-25
US201562252171P 2015-11-06 2015-11-06
US201562263544P 2015-12-04 2015-12-04
US201662354592P 2016-06-24 2016-06-24
PCT/US2016/052383 WO2017049251A2 (en) 2015-09-18 2016-09-17 Therapeutic cd47 antibodies

Publications (1)

Publication Number Publication Date
ZA201804326B true ZA201804326B (en) 2019-09-25

Family

ID=58289729

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2018/04326A ZA201804326B (en) 2015-09-18 2018-06-27 Therapeutic cd47 antibodies

Country Status (15)

Country Link
US (3) US10239945B2 (cg-RX-API-DMAC7.html)
EP (1) EP3349787A4 (cg-RX-API-DMAC7.html)
JP (1) JP6885606B2 (cg-RX-API-DMAC7.html)
CN (2) CN116425875A (cg-RX-API-DMAC7.html)
AU (1) AU2016324316B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018005322A2 (cg-RX-API-DMAC7.html)
CA (1) CA2998644A1 (cg-RX-API-DMAC7.html)
IL (1) IL258168A (cg-RX-API-DMAC7.html)
MX (1) MX2018003374A (cg-RX-API-DMAC7.html)
NZ (1) NZ740686A (cg-RX-API-DMAC7.html)
PH (1) PH12018500515A1 (cg-RX-API-DMAC7.html)
RU (1) RU2748401C2 (cg-RX-API-DMAC7.html)
UA (1) UA126146C2 (cg-RX-API-DMAC7.html)
WO (1) WO2017049251A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201804326B (cg-RX-API-DMAC7.html)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9221908B2 (en) 2012-12-12 2015-12-29 Vasculox, Inc. Therapeutic CD47 antibodies
JP6572131B2 (ja) 2012-12-12 2019-09-04 バスキュロックス インコーポレイテッド 治療用ｃｄ４７抗体
EA037654B1 (ru) 2014-12-30 2021-04-27 Селджин Корпорейшн Анти-cd47-антитела и их применения
JP6885606B2 (ja) 2015-09-18 2021-06-16 アーチ オンコロジー, インコーポレイテッドArch Oncology, Inc. 治療用ｃｄ４７抗体
EP3529276A4 (en) 2016-10-21 2020-06-17 Arch Oncology, Inc. CD47 THERAPEUTIC ANTIBODIES
CA3057139A1 (en) * 2017-03-22 2018-09-27 Arch Oncology, Inc. Combination therapy for the treatment of solid and hematological cancers
BR112019021520A2 (pt) 2017-04-14 2020-08-04 Tollnine, Inc. oligonucleotídeo, composto, polinucleotídeo imunomodulador, composição, conjugado, método para modular um receptor, método de tratamento de um tumor, método de tratamento de câncer, método para tratar um tumor, método de prevenção de câncer, método para induzir uma resposta imune
NZ761568A (en) * 2017-08-02 2022-11-25 Phanes Therapeutics Inc Anti-cd47 antibodies and uses thereof
JP7256580B2 (ja) * 2017-08-18 2023-04-12 ウルトラヒューマン フォー リミティド 結合剤
CN109422811A (zh) 2017-08-29 2019-03-05 信达生物制药(苏州)有限公司 抗cd47抗体及其用途
AU2018351006B2 (en) * 2017-10-18 2024-08-29 Forty Seven, LLC Anti-CD47 agent-based ovarian cancer therapy
WO2019079549A1 (en) * 2017-10-18 2019-04-25 Forty Seven, Inc. TREATMENT OF OVARY CANCER BY ANTI-CD47 AND ANTI-PD-L1
WO2019086574A1 (en) * 2017-11-01 2019-05-09 Hummingbird Bioscience Holdings Pte. Ltd. Cd47 and cd33 antigen-binding molecules
CA3080860A1 (en) * 2017-11-01 2019-05-09 Hummingbird Bioscience Holdings Pte. Ltd. Cd47 antigen-binding molecules
GB201720426D0 (en) * 2017-12-07 2018-01-24 Hummingbird Bioscience Pte Ltd CD47 and BCMA antigen-binding molecules
US11180552B2 (en) 2017-12-01 2021-11-23 Seagen Inc. CD47 antibodies and uses thereof for treating cancer
JP7231641B2 (ja) * 2017-12-04 2023-03-01 北京韓美薬品有限公司 天然抗体様構造を有し、ヘテロ二量体形態の抗ｐｄ－ｌ１／抗ｃｄ４７二重特異性抗体、ならびにその製造方法
CN110144009B (zh) * 2018-02-14 2020-01-21 上海洛启生物医药技术有限公司 Cd47单域抗体及其用途
WO2019179366A1 (en) * 2018-03-20 2019-09-26 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-cd47 antibodies
CN110305212A (zh) * 2018-03-27 2019-10-08 信达生物制药(苏州)有限公司 抗cd47抗体及其用途
GB201804860D0 (en) 2018-03-27 2018-05-09 Ultrahuman Two Ltd CD47 Binding agents
CN110577597B (zh) * 2018-06-11 2021-10-22 康诺亚生物医药科技（成都）有限公司 一种阻断CD47和SIRPα相互作用的抗体
CN108872569A (zh) * 2018-06-19 2018-11-23 浠思（上海）生物技术有限公司 利用HTRF一步法筛选CD47/SIRP alpha阻断剂的方法
EP3817769A4 (en) * 2018-07-05 2022-03-30 Trican Biotechnology Co., Ltd Human anti-cd47 antibodies and uses thereof
WO2020019135A1 (zh) * 2018-07-23 2020-01-30 中国科学院微生物研究所 一种抗cd47抗体及其应用
US20210324075A1 (en) * 2018-08-13 2021-10-21 Arch Oncology, Inc. Therapeutic cd47 antibodies
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
US11202828B2 (en) * 2018-11-14 2021-12-21 Arch Oncology, Inc. Therapeutic SIRP-α antibodies
EP3894439A4 (en) * 2018-12-14 2022-11-30 Boehringer Ingelheim IO Canada Inc. ANTI-PERIOSTIN ANTIBODIES AND THEIR USES
CN109550047A (zh) * 2019-01-16 2019-04-02 中国药科大学 抗cd47抗体在制备防治心力衰竭的药物中的应用
WO2020163721A1 (en) * 2019-02-08 2020-08-13 Integrity Bioventures, Inc. Anti-cd47 antibodies and uses thereof
WO2020210719A1 (en) 2019-04-10 2020-10-15 Elevatebio Management, Inc. Flt3-specific chimeric antigen receptors and methods of using the same
CN114072172B (zh) * 2019-04-18 2025-05-13 Qlsf生物治疗药物公司 靶向人cd47的抗体
CN114206912B (zh) 2019-06-07 2025-02-11 Alx肿瘤生物技术公司 用于在血清学测定中减少结合cd47的药物的干扰的方法和试剂
CN113993899B (zh) * 2019-06-19 2024-03-29 乐普生物科技股份有限公司 抗cd47抗体及其应用
CN120775062A (zh) 2019-07-16 2025-10-14 吉利德科学公司 Hiv疫苗及其制备和使用方法
CN112239507A (zh) * 2019-07-17 2021-01-19 鸿运华宁（杭州）生物医药有限公司 ETA抗体与TGF-β Trap的融合蛋白质，以及其药物组合物和应用
AU2020342192A1 (en) * 2019-09-03 2022-04-21 Akeso Biopharma, Inc Anti-CD47 monoclonal antibody and use thereof
WO2021046216A1 (en) * 2019-09-03 2021-03-11 Arch Oncology, Inc. Methods for identifying biomarkers to predict treatment response
US11655303B2 (en) * 2019-09-16 2023-05-23 Surface Oncology, Inc. Anti-CD39 antibody compositions and methods
CN118178645A (zh) 2019-10-18 2024-06-14 四十七公司 用于治疗骨髓增生异常综合征和急性髓系白血病的联合疗法
WO2021080920A2 (en) * 2019-10-23 2021-04-29 Arch Oncology, Inc. Combination therapy for the treatment of solid and hematological cancers
KR102866810B1 (ko) * 2019-10-25 2025-09-30 우시 바이올로직스 아일랜드 리미티드 신규한 항-cd47 항체 및 그 용도
CA3153636A1 (en) 2019-10-31 2021-05-06 Forty Seven, Inc. Anti-cd47 and anti-cd20 based treatment of blood cancer
IL293926A (en) 2019-12-17 2022-08-01 Pfizer Antibodies specific for cd47, pd-l1, and uses thereof
AU2020412875A1 (en) 2019-12-24 2022-06-23 Carna Biosciences, Inc. Diacylglycerol kinase modulating compounds
PH12022552122A1 (en) 2020-02-14 2024-01-29 Jounce Therapeutics Inc Antibodies and fusion proteins that bind to ccr8 and uses thereof
MX2022010515A (es) 2020-02-28 2022-11-14 Tallac Therapeutics Inc Conjugacion mediada por transglutaminasa.
WO2021188631A1 (en) * 2020-03-18 2021-09-23 Kindred Biosciences, Inc. Anti-il4 receptor antibodies for veterinary use
US12091681B2 (en) 2020-03-27 2024-09-17 Mendus B.V. Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
AR121805A1 (es) * 2020-04-10 2022-07-13 Hutchison Medipharma Ltd Anticuerpo anti-cd47 y usos del mismo
WO2021262765A1 (en) 2020-06-22 2021-12-30 The Board Of Trustees Of The Leland Stanford Junior University Tsp-1 inhibitors for the treatment of aged, atrophied or dystrophied muscle
WO2022003568A1 (en) 2020-06-30 2022-01-06 Dcprime B.V. Use of leukemia-derived cells in ovarian cancer vaccines
CN114057876B (zh) * 2020-07-31 2025-03-21 百奥泰生物制药股份有限公司 Cd47抗体及其应用
US20220196651A1 (en) 2020-12-06 2022-06-23 ALX Oncology Inc. Multimers for reducing the interference of drugs that bind cd47 in serological assays
EP4304633A1 (en) 2021-03-12 2024-01-17 Mendus B.V. Methods of vaccination and use of cd47 blockade
US20240190993A1 (en) 2021-04-14 2024-06-13 INSERM (Institut National de la Santé et de la Recherche Médicale) New method to improve the anti-tumoral activity of macrophages
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
US11932634B2 (en) 2021-06-23 2024-03-19 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
KR20240023628A (ko) 2021-06-23 2024-02-22 길리애드 사이언시즈, 인코포레이티드 디아실글리세롤 키나제 조절 화합물
CN117396478A (zh) 2021-06-23 2024-01-12 吉利德科学公司 二酰基甘油激酶调节化合物
KR20240023629A (ko) 2021-06-23 2024-02-22 길리애드 사이언시즈, 인코포레이티드 디아실글리세롤 키나제 조절 화합물
WO2023278778A1 (en) * 2021-06-30 2023-01-05 Ohio State Innovation Foundation Methods and compositions for inhibition of dihydroorotate dehydrogenase in combination with an anti-cd47-sirpα therapeutic agent
US20240368279A1 (en) * 2021-08-24 2024-11-07 Shanghai Sinobay Biotechnology Co., Ltd. Antibody Specifically Binding to CD47, Recombinant Oncolytic Virus Thereof and Use Thereof
AU2022375782A1 (en) 2021-10-28 2024-05-02 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
US11919869B2 (en) 2021-10-29 2024-03-05 Gilead Sciences, Inc. CD73 compounds
CN118488946A (zh) 2021-12-22 2024-08-13 吉利德科学公司 Ikaros锌指家族降解剂及其用途
CA3237577A1 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
EP4479084A1 (en) 2022-02-14 2024-12-25 Sana Biotechnology, Inc. Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells
ES2999273T3 (en) 2022-03-17 2025-02-25 Gilead Sciences Inc Ikaros zinc finger family degraders and uses thereof
WO2023183313A1 (en) 2022-03-22 2023-09-28 Sana Biotechnology, Inc. Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods
JP2025509662A (ja) 2022-03-24 2025-04-11 ギリアード サイエンシーズ， インコーポレイテッド Ｔｒｏｐ－２発現がんを治療するための併用療法
TWI876305B (zh) 2022-04-05 2025-03-11 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
KR20250004824A (ko) 2022-04-21 2025-01-08 길리애드 사이언시즈, 인코포레이티드 Kras g12d 조절 화합물
WO2024006929A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Cd73 compounds
EP4554628A1 (en) 2022-07-12 2025-05-21 Gilead Sciences, Inc. Hiv immunogenic polypeptides and vaccines and uses thereof
WO2024064668A1 (en) 2022-09-21 2024-03-28 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
AU2023409398A1 (en) 2022-12-22 2025-06-05 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2024215754A1 (en) 2023-04-11 2024-10-17 Gilead Sciences, Inc. Kras modulating compounds
WO2024220917A1 (en) 2023-04-21 2024-10-24 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2025006720A1 (en) 2023-06-30 2025-01-02 Gilead Sciences, Inc. Kras modulating compounds
WO2025024663A1 (en) 2023-07-26 2025-01-30 Gilead Sciences, Inc. Parp7 inhibitors
US20250100998A1 (en) 2023-07-26 2025-03-27 Gilead Sciences, Inc. Parp7 inhibitors
WO2025054530A1 (en) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
US20250101042A1 (en) 2023-09-08 2025-03-27 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250154172A1 (en) 2023-11-03 2025-05-15 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors
CN120714022A (zh) * 2024-03-27 2025-09-30 康方汇科(上海)生物有限公司 药物组合及用途
US20250376484A1 (en) 2024-05-21 2025-12-11 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0256654B1 (en) 1986-07-07 1996-09-18 Centocor, Inc. Chimeric murine/human immunoglobulin specific for tumour-associated 17-1A Antigen
DE69839492D1 (de) 1997-09-11 2008-06-26 Chugai Pharmaceutical Co Ltd Monoklonale antikörper zur apoptosis-induzierung
US7531643B2 (en) 1997-09-11 2009-05-12 Chugai Seiyaku Kabushiki Kaisha Monoclonal antibody inducing apoptosis
CA2226962A1 (en) 1998-02-16 1999-08-16 Marie Sarfati Use of binding agents to cd47 and its ligands in the treatment or the prophylaxis of various inflammatory, autoimmune and allergic diseases and in the treatment of graft rejection
DE19813759C1 (de) 1998-03-27 1999-07-15 Gsf Forschungszentrum Umwelt Verfahren zur Induktion einer durch NK-Zellen vermittelten Immunantwort
US7696325B2 (en) 1999-03-10 2010-04-13 Chugai Seiyaku Kabushiki Kaisha Polypeptide inducing apoptosis
EP1167388A4 (en) * 1999-03-10 2002-05-29 Chugai Pharmaceutical Co Ltd APOPTOSE INDUCING SINGLE STRING FV
CN1335887A (zh) 1999-06-21 2002-02-13 印坎药物股份有限公司 血管抑制素∶一种Cys－Ser－Val－Thr－Cys－Gly特异性肿瘤细胞粘附受体
AU6698900A (en) 1999-07-16 2001-02-05 Agricultural Research Service Live recombinant vaccine against avian leukosis virus using a marek's disease virus (mdv) virus as vector
US20010041670A1 (en) 1999-12-06 2001-11-15 Ronit Simantov Thrombospondin-binding region of histidine-rich glycoprotein and method of use
US7282556B2 (en) * 2001-05-15 2007-10-16 Emory University Polynucleotides and polypeptides relating to the modulation of SIRPα-CD47
EP1519735A4 (en) 2001-12-12 2006-01-11 Conforma Therapeutic Corp ASSAYS AND DEVICES FOR DETERMINING AND MODULATING HSP90 BINDING ACTIVITY
US20040213792A1 (en) 2003-04-24 2004-10-28 Clemmons David R. Method for inhibiting cellular activation by insulin-like growth factor-1
EP1693385A4 (en) 2003-11-11 2009-11-04 Chugai Pharmaceutical Co Ltd ANTI-CD47 ANTIBODIES HUMANIZED
WO2006031653A2 (en) 2004-09-10 2006-03-23 Wyeth Humanized anti-5t4 antibodies and anti-5t4 antibody / calicheamicin conjugates
JP2007008895A (ja) 2005-07-04 2007-01-18 Chugai Pharmaceut Co Ltd 抗ｃｄ４７抗体とインテグリンリガンドとの併用
US7514229B2 (en) 2005-09-29 2009-04-07 The Board Of Trustees Of The Leland Stanford Junior University Methods for diagnosing and evaluating treatment of blood disorders
SG170091A1 (en) 2006-03-10 2011-04-29 Wyeth Corp Anti-5t4 antibodies and uses thereof
WO2008043072A2 (en) 2006-10-05 2008-04-10 Biogen Idec Inc. Cd80 antagonists for treating neoplastic disorders
US8236313B2 (en) 2006-10-06 2012-08-07 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Prevention of tissue ischemia, related methods and compositions
HUE050958T2 (hu) 2008-01-15 2021-01-28 Univ Leland Stanford Junior Akut mieloid leukémia õssejtek markerei
PT3056515T (pt) 2008-01-15 2019-07-19 Univ Leland Stanford Junior Métodos para manipulação da fagocitose mediada por cd47
AU2014201010B2 (en) * 2008-01-15 2016-03-03 The Board Of Trustees Of The Leland Stanford Junior University Methods for manipulating phagocytosis mediated by CD47
BRPI0907718A2 (pt) 2008-02-11 2017-06-13 Curetech Ltd método para tratar um tumor, método para melhorar a tolerabilidade a pelo menos um agente quimiterápico, método para aumentar a sobrevida de um indivíduo que tem um tumor, método para reduzir ou prevenir recidiva tumoral, uso de um anticorpo monoclonal humanizado ou seu fragmento e anticorpo monoclonal humanizado ou seu fragmento
DK3031825T3 (da) * 2008-03-14 2019-10-28 Allergan Inc Immunbaserede aktivitetsassays for botulinum-toxin serotype a
KR101604515B1 (ko) * 2008-03-14 2016-03-17 알러간, 인코포레이티드 면역-기반 보툴리눔 독소 세로타입 ａ 활성 검정
EP2111869A1 (en) 2008-04-23 2009-10-28 Stichting Sanquin Bloedvoorziening Compositions and methods to enhance the immune system
EP2340034B2 (en) 2008-08-07 2019-02-13 The United States Of America, As Represented By The Secretary, Department of Health and Human Services Radioprotectants targeting thrombospondin-1 and cd47
EP4134095A1 (en) 2009-09-15 2023-02-15 The Board of Trustees of the Leland Stanford Junior University Synergistic anti-cd47 therapy for hematologic cancers
WO2011083141A2 (en) * 2010-01-08 2011-07-14 Ablynx Nv Method for generation of immunoglobulin sequences by using lipoprotein particles
CN102812041A (zh) 2010-01-21 2012-12-05 英穆尔诺基公司 治疗卵巢癌的组合物及方法
HUE060541T2 (hu) 2010-05-14 2023-03-28 Univ Leland Stanford Junior Humanizált és kiméra monoklonális CD47 elleni ellenanyagok
WO2012047427A2 (en) * 2010-08-31 2012-04-12 The Regents Of The University Of California Antibodies for botulinum neurotoxins
US20140271683A1 (en) 2010-12-21 2014-09-18 The Board Of Trustees Of The Leland Stanford Junior University Therapeutic and Diagnostic Methods for Manipulating Phagocytosis Through Calreticulin and Low Density Lipoprotein-Related Receptor
SMT201900453T1 (it) * 2012-02-06 2019-11-13 Inhibrx Inc Anticorpi anti cd47 e relativi metodi d'uso
US20140140989A1 (en) 2012-02-06 2014-05-22 Inhibrx Llc Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof
KR20150023811A (ko) 2012-06-21 2015-03-05 컴퓨젠 엘티디. 암의 치료를 위한 lsr 항체 및 그의 용도
DK2925782T3 (da) * 2012-12-03 2020-04-06 Novimmune Sa Anti-cd47-antistoffer og fremgangsmåder til anvendelse deraf
US9221908B2 (en) 2012-12-12 2015-12-29 Vasculox, Inc. Therapeutic CD47 antibodies
JP6572131B2 (ja) 2012-12-12 2019-09-04 バスキュロックス インコーポレイテッド 治療用ｃｄ４７抗体
KR102276974B1 (ko) * 2013-02-06 2021-07-13 인히브릭스, 인크. 비-혈소판 및 비-적혈구 세포 격감성 cd47 항체 및 이를 이용하는 방법
CN112245586A (zh) 2013-03-15 2021-01-22 小利兰·斯坦福大学托管委员会 用于实现治疗有效剂量的抗cd47剂的方法
CN103665165B (zh) * 2013-08-28 2016-02-24 江苏匡亚生物医药科技有限公司 一种靶向人CD47-SIRPα信号通路的双特异性抗体及其制备方法和用途
CN105263959A (zh) 2013-12-31 2016-01-20 财团法人生物技术开发中心 抗vegf抗体及其用途
JP6885606B2 (ja) 2015-09-18 2021-06-16 アーチ オンコロジー, インコーポレイテッドArch Oncology, Inc. 治療用ｃｄ４７抗体
US10946042B2 (en) 2015-12-01 2021-03-16 The Trustees Of The University Of Pennsylvania Compositions and methods for selective phagocytosis of human cancer cells
EP3529276A4 (en) 2016-10-21 2020-06-17 Arch Oncology, Inc. CD47 THERAPEUTIC ANTIBODIES
CA3057139A1 (en) 2017-03-22 2018-09-27 Arch Oncology, Inc. Combination therapy for the treatment of solid and hematological cancers
US20190309066A1 (en) 2017-03-22 2019-10-10 Arch Oncology, Inc. Combination therapy for the treatment of solid and hematological cancers

Also Published As

Publication number Publication date
US20190300611A1 (en) 2019-10-03
AU2016324316A1 (en) 2018-04-05
US10239945B2 (en) 2019-03-26
CA2998644A1 (en) 2017-03-23
BR112018005322A2 (pt) 2018-12-11
CN116425875A (zh) 2023-07-14
WO2017049251A2 (en) 2017-03-23
NZ740686A (en) 2021-12-24
US10844124B2 (en) 2020-11-24
EP3349787A2 (en) 2018-07-25
EP3349787A4 (en) 2019-03-27
MX2018003374A (es) 2018-11-09
CN108348589A (zh) 2018-07-31
IL258168A (en) 2018-05-31
JP2018536624A (ja) 2018-12-13
UA126146C2 (uk) 2022-08-25
US20180171014A1 (en) 2018-06-21
JP6885606B2 (ja) 2021-06-16
CN108348589B (zh) 2022-09-23
US20210070865A1 (en) 2021-03-11
PH12018500515A1 (en) 2018-08-29
RU2748401C2 (ru) 2021-05-25
RU2018124859A (ru) 2020-01-14
WO2017049251A3 (en) 2017-04-20
AU2016324316B2 (en) 2023-02-09
RU2018124859A3 (cg-RX-API-DMAC7.html) 2020-06-05

Similar Documents

Publication Publication Date Title
ZA201804326B (en) Therapeutic cd47 antibodies
IL259048A (en) Antibodies against ror-1
ZA201708128B (en) Tau-binding antibodies
EP3529276A4 (en) CD47 THERAPEUTIC ANTIBODIES
SG10201913864RA (en) Anti-LAG-3 Antibodies
ZA201705663B (en) Anti-transthyretin antibodies
ZA201800027B (en) Tau-binding antibodies
HUE066594T2 (hu) Anti-GARP antitest
GB201521393D0 (en) Antibodies
GB201521391D0 (en) Antibodies
SG11201706126WA (en) Anti-transthyretin antibodies
GB201521382D0 (en) Antibodies
IL255323A0 (en) Anti-fcrn antibodies
ZA201705662B (en) Anti-transthyretin antibodies
GB201515351D0 (en) Antibody
GB201505239D0 (en) Antibody
SG11201800864XA (en) Antibody
GB201509907D0 (en) Antibodies
GB201522394D0 (en) Antibodies
GB201503438D0 (en) Antibodies
IL284022A (en) Anti-transthyretin antibodies
HK1258791A1 (en) Therapeutic cd47 antibodies
GB201509493D0 (en) Therapeutic antibody
GB201518728D0 (en) Antibodies
GB201515572D0 (en) Anti-LAG-3 antibodies